# Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

> **NCT05804370** · PHASE3 · RECRUITING · sponsor: **NX Development Corp** · enrollment: 170 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Gleolan

## Key facts

- **NCT ID:** NCT05804370
- **Lead sponsor:** NX Development Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2027-01
- **Final completion:** 2027-05
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804370, "Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05804370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*